Navigation Links
Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
Date:5/26/2009

MALVERN, Pa., May 26 /PRNewswire/ -- Ascenta Therapeutics announced today that eleven presentations or publications on pre-clinical and clinical studies of AT-101, an oral, pan-Bcl-2 inhibitor, in several major tumor types will be made during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida. Abstracts are available at www.asco.org.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO )

Prostate Cancer

MacVicar G, et al. An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate resistant prostate cancer (CRPC). Abstract #5062; Poster Board #17; Poster Discussion, May 31, 8:00 a.m.-12:00 p.m.

Poiesz B, et al. Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer. Abstract #5145; Poster Board #J13; GU General Poster Session, May 31, 2:00 p.m.-6:00 p.m.

Glioma

Fiveash J, et al. NABT-0702: A phase II study of AT-101 in recurrent glioblastoma multiforme (GBM). Abstract #2010; Poster Board #2; Poster Discussion, May 30, 8:00 a.m.-12:00 p.m.

Lung Cancer

Heist R, et al. A phase I/II study of AT-101 in combination with topotecan (T) in patients with relapsed or refractory small cell lung cancer (SCLC) after prior platinum containing first line chemotherapy. Abstract #8106; Poster Board #R14; Lung Cancer - Metastatic, May 30, 2:00 p.m.-6:00 p.m.

Ready N, et al. AT-101 or placebo (P) with docetaxel (D) in second line NSCLC with gene signature biomarker development. Abstract #3577; Poster Board #J19; Developmental Therapeutics, May 30, 8:00 a.m.-12:00 p.m.

Min P, et al. Small molecule pan-bcl-2 inhibitor AT-101 induces apoptosis in NSCLC by upregulating noxa and enhances antitumor activity of docetaxel or targeted kinase inhibitors. Abstract #e14591; Publication only.

Non-Hodgkin's Lymphoma

Kingsley E, et al. An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade I-II, follicular Non-Hodgkin's Lymphoma (FL). Abstract #8582; Poster Board #S11; Lymphoma and Plasma Cell Disorders, May 30, 8:00 a.m.-12:00 p.m.

Advanced Cancers

Leal TB, et al. A phase I study of AT-101 in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC). Abstract #e13502; Publication only.

Saleh M, et al. Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers. Abstract #e14537; Publication only.

Mechanism of Action/Pharmacokinetics

Wang S, et al. AT-101 induces transcriptional up-regulation of Noxa and Puma and overcomes Mcl-1-mediated cancer cell resistance to apoptosis. Abstract # e14611; Publication only.

Pitot H, et al. Analysis of a phase I pharmacokinetic (PK)/food effect study of AT-101 in patients with advanced solid tumors. Abstract #2557; Poster Board #B18; Developmental Therapeutics, May 30, 8:00 a.m.-12:00 p.m.

About AT-101

AT-101 is an orally-active, pan-Bcl-2 inhibitor (including Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 inhibition) that has been shown to induce apoptosis directly by operating as a BH3 mimetic and indirectly as an independent upregulator of Noxa and Puma. By blocking the binding of Bcl-2 family members with proapoptotic proteins and upregulating specific proapoptotic factors, AT-101 lowers the threshold for cancer cells to undergo apoptosis in various tumor types. In Phase I and Phase II trials, AT-101 has demonstrated single-agent cytoreductive activity in several cancers, including chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), and prostate cancer. Phase II combination trials are ongoing in several cancers, including hormone-refractory prostate cancer and non-small cell lung cancer (with Taxotere(R)), B-cell malignancies (with Rituxan(R)), small cell lung cancer (with Hycamtin(R)), glioma (with Temodar(R), +/- chemoradiotherapy [XRT]) and esophageal cancer (with docetaxel, 5-fluorouracil and XRT).

About Ascenta Therapeutics

Ascenta Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company that discovers and develops new medicines for the treatment of cancer. The company is headquartered in Malvern, Pennsylvania, and has a preclinical research facility in Shanghai, China. Its technology, licensed from both the National Institutes of Health and the laboratory of Dr. Shaomeng Wang at the University of Michigan, is focused on discovering molecules that restore the natural potential for cancer cells to undergo cell death (apoptosis). Ascenta's lead agent, AT-101, is an orally-active small molecule pan Bcl-2 inhibitor (Bcl-2, Bcl-xL, and Mcl-1) currently in Phase 2 clinical trials in castrate resistant prostate cancer. The Company's preclinical pipeline includes the oral multi-IAP antagonist AT-406, and an HDM2-p53 inhibitor program.

For additional information on Ascenta Therapeutics, please visit the company's website at www.ascenta.com


'/>"/>
SOURCE Ascenta Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
2. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
3. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
4. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
5. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
6. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
7. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
8. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
9. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
10. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):